SBIO - ETF AI Analysis

Top Page

ALPS Medical Breakthroughs ETF (SBIO)

Rating:54Neutral

Price Target:―

The ALPS Medical Breakthroughs ETF (SBIO) has a moderate overall rating, reflecting a mix of strengths and challenges among its holdings. Alkermes stands out as a key contributor to the fund's rating, driven by its strong financial performance, strategic acquisitions, and robust profitability. However, weaker holdings like Celcuity and Apogee Therapeutics, both facing significant financial risks and valuation concerns, weigh down the ETF's overall score. A primary risk factor for SBIO is its concentration in early-stage biotech companies, which often experience high volatility and financial uncertainty.

Positive Factors

Strong Top Holdings

Several top holdings, such as Merus and Metsera, have delivered strong year-to-date performance, driving the ETF’s overall gains.

Focused Sector Exposure

The ETF is heavily concentrated in the health care sector, which has shown resilience and growth potential in recent periods.

Healthy Year-to-Date Performance

The fund has delivered strong year-to-date returns, indicating positive momentum in its portfolio.

Negative Factors

High Sector Concentration

With nearly all assets in the health care sector, the ETF is vulnerable to industry-specific risks.

Limited Geographic Diversification

The fund is almost entirely focused on U.S.-based companies, offering little exposure to international markets.

Mixed Performance Among Holdings

Some holdings, like Vaxcyte, have underperformed, which could weigh on the ETF’s future returns.

SBIO vs. SPDR S&P 500 ETF (SPY)

AUM127.72M

RegionNorth America

Expense Ratio0.50%

Beta1.15

IssuerALPS

Inception DateDec 31, 2014

Dividend YieldN/A

Asset ClassEquity

Index TrackedS-Network Medical Breakthroughs Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume43,749

30 Day Avg. Volume42,689

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

82.01

Price Target Upside― Downside

Rating ConsensusStrong Buy

Number of Analyst Covering87

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

SBIO Summary

The ALPS Medical Breakthroughs ETF (SBIO) is an investment fund focused on small to mid-sized biotechnology companies in the health care sector. It includes firms developing cutting-edge treatments, with many having drugs in advanced clinical trials. Some of its top holdings are Rhythm Pharmaceuticals and Avidity Biosciences, which are working on innovative therapies. This ETF could appeal to investors looking for growth opportunities in medical innovation. However, it’s important to note that the ETF is heavily tied to the biotech industry, which can be volatile and influenced by the success or failure of clinical trials.

How much will it cost me?The ALPS Medical Breakthroughs ETF (SBIO) has an expense ratio of 0.50%, meaning you’ll pay $5 per year for every $1,000 invested. This is slightly higher than average because it’s actively managed and focuses on specialized biotechnology companies, which require more research and expertise to manage effectively.

What would affect this ETF?The ALPS Medical Breakthroughs ETF (SBIO) could benefit from increased demand for innovative health care solutions and advancements in biotechnology, especially as its holdings focus on companies developing groundbreaking treatments in clinical trials. However, the ETF may face challenges from regulatory hurdles, high research and development costs, or broader economic pressures that could impact small to mid-cap biotech firms. Changes in interest rates or shifts in investor sentiment toward riskier assets could also influence its performance.

SBIO Top 10 Holdings

The ALPS Medical Breakthroughs ETF (SBIO) is a biotech-focused fund with a clear emphasis on small to mid-cap innovators in the U.S. health care sector. Celcuity is a standout performer, riding strong clinical trial momentum, while Apogee Therapeutics is also rising thanks to positive trial results and a solid cash position. On the other hand, Viking Therapeutics and Alkermes are lagging slightly, weighed down by operational losses and valuation concerns. With its concentrated exposure to cutting-edge biotech firms, SBIO offers a high-risk, high-reward play on the future of medical innovation.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
KYMR	Kymera Therapeutics	4.08%	$5.27M	$6.59B	104.63%	56 Neutral
CELC	Celcuity	2.95%	$3.81M	$4.74B	716.84%	44 Neutral
ACAD	ACADIA Pharmaceuticals	2.93%	$3.79M	$4.71B	63.03%	75 Outperform
ALKS	Alkermes	2.93%	$3.78M	$4.70B	-3.91%	80 Outperform
CRNX	Crinetics Pharmaceuticals	2.87%	$3.71M	$4.64B	-9.40%	61 Neutral
FOLD	Amicus	2.73%	$3.53M	$4.40B	45.15%	73 Outperform
APGE	Apogee Therapeutics	2.66%	$3.44M	$5.28B	63.36%	49 Neutral
GPCR	Structure Therapeutics, Inc. Sponsored ADR	2.63%	$3.40M	$4.33B	152.35%	31 Underperform
VKTX	Viking Therapeutics	2.62%	$3.39M	$4.12B	-14.02%	53 Neutral
MIRM	Mirum Pharmaceuticals	2.58%	$3.33M	$4.14B	89.83%	56 Neutral

SBIO Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

47.02

Positive

100DMA

41.77

Positive

200DMA

35.76

Positive

Market Momentum

MACD

1.44

Positive

RSI

68.96

Neutral

STOCH

90.65

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SBIO, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 50.50, equal to the 50-day MA of 47.02, and equal to the 200-day MA of 35.76, indicating a bullish trend. The MACD of 1.44 indicates Positive momentum. The RSI at 68.96 is Neutral, neither overbought nor oversold. The STOCH value of 90.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SBIO.

SBIO Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
SBIO	―	―	$127.72M	0.50%	―
FXH	―	―	$954.13M	0.62%	―
IHE	―	―	$857.71M	0.38%	―
RSPH	―	―	$755.40M	0.40%	―
IHF	―	―	$745.07M	0.38%	―
PBE	―	―	$260.46M	0.58%	―

Performance Comparison

SBIO

ALPS Medical Breakthroughs ETF

52.90

18.49

53.73%

FXH

First Trust Health Care AlphaDEX Fund

―

IHE

iShares U.S. Pharmaceuticals ETF

―

RSPH

Invesco S&P 500 Equal Weight Health Care ETF

―

IHF

iShares U.S. Healthcare Providers ETF

―

PBE

Invesco Dynamic Biotechnology & Genome ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents